Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liebhaber, M. I.
Right arrow Articles by Kupperman, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liebhaber, M. I.
Right arrow Articles by Kupperman, J. L.
(Chest. 1999;115:886-889.)
© 1999 American College of Chest Physicians

Polymyalgia, Hypersensitivity Pneumonitis and Other Reactions in Patients Receiving HMG-CoA Reductase Inhibitors*

A Report of Ten Cases

Myron I. Liebhaber, MD; Robert S. Wright, MD, FCCP; Harris J. Gelberg, MD; Zeb Dyer, PA and Jeffrey L. Kupperman, MD, FCCP

* From the Department of Medicine and Pediatrics (Drs. Liebhaber and Wright), UCLA School of Medicine, Los Angeles, CA; Department of Medicine (Drs. Gelberg and Kupperman), USC School of Medicine, Los Angeles, CA; and Santa Barbara Medical Foundation Clinic (Dr. Dyer), Santa Barbara, CA.

Since 1980, hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have become the most prescribed cholesterol-lowering drugs. They are effective and have been shown to lower the incidence of stroke, cardiovascular disease, and mortality.1 By inhibiting the HMG-CoA reductase, which is a rate-limiting enzyme in the biosynthesis of cholesterol, these drugs increase the number of low-density lipoprotein receptors in the liver and, therefore, decrease serum low-density lipoprotein cholesterol. They have an excellent safety profile with a low frequency of side effects.2 Recently we have encountered a series of patients with evidence of hypersensitivity to HMG-CoA reductase inhibitors, or statin drugs. We are reporting our experience with 10 patients: two with potentially life-threatening reactions and one with biopsy evidence of hypersensitivity pneumonitis. We are aware of only two previous cases of interstitial lung disease in association with statin medications.3 ,4

Key Words: HMG-CoA reductase inhibitors • hypersensitivity • pneumonitis • statin




This article has been cited by other articles:


Home page
 Eur Respir JHome page
J-M. Naccache, M. Kambouchner, F. Girard, M. Antoine, A. Parrot, J. Piquet, M. Brauner, and D. Valeyre
Relapse of respiratory insufficiency one year after organising pneumonia
Eur. Respir. J., December 1, 2004; 24(6): 1062 - 1065.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
K. LeBlanc and M. T. Brophy
Simvastatin
Ann Intern Med, June 17, 2003; 138(12): W-53 - W-53.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Lantuejoul, E. Brambilla, C. Brambilla, and G. Devouassoux
Statin-induced fibrotic nonspecific interstitial pneumonia
Eur. Respir. J., March 1, 2002; 19(3): 577 - 580.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.